Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects

Phase 1 Completed 14 enrolled Jiangsu HengRui Medicine Co., Ltd.

NaSequentialOpen-labelTreatment

Summary

This study is a single-center, open-label, sequential drug interaction study The primary objectives are: To evaluate the pharmacokinetic effects of HRS-8427 injection on the liver drug enzymes CYP2B6 substrate bupropion and CYP3A4 substrate midazolam in healthy subjects.

Timeline

Start: 2025-06-23
Primary completion: 2025-07-21
Completion: 2025-07-21

Publications

Yin T, Qu B, Zhang Q, Xu S, Wu Y, Jiang H, Huang Y, Hu W. Pharmacokinetics, safety, and tolerability of HRS-8427, a novel anti-carbapenem-resistant cephalosporin, in healthy subjects. Antimicrob Agents Chemother. 2026 Apr;70(4):e0069425. doi: 10.1128/aac.00694-25. Epub 2026 Mar 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HRS-8427	Small molecule	—	Intravenous

Indications

No indication recorded.